Back to top
more

Cidara Therapeutics (CDTX)

(Delayed Data from NSDQ)

$61.99 USD

61.99
561,040

+0.22 (0.36%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $62.00 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice

by Zacks Equity Research

Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

by Zacks Equity Research

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Zacks Equity Research

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 15.60% and 6.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.45% and 7.57%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Cidara (CDTX) stock based on the movements in the options market lately.

Zacks Equity Research

Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.